Literature DB >> 25145299

CXCR4 promotes GSK3β expression in pancreatic cancer cells via the Akt pathway.

Shijie Ma1, Qianjun Li, Feng Pan.   

Abstract

BACKGROUND: CXCR4 and glycogen synthase kinase-3β (GSK3β) promote proliferation and invasion of pancreatic cancer. Inhibition of CXCR4 suppresses GSK3β expression. However, the molecular mechanism by which CXCR4 contributes to human pancreatic cancer metastasis is not completely understood. In this study, therefore, we analyzed the effect of CXCR4 on GSK3β expression and its molecular mechanism.
METHODS: PANC-1 and SW-1990 cells were used in this study. PANC-1 and SW-1990 cell lines which stably expressed upregulated or downregulated CXCR4 were used for further study. Western blotting was employed to detected the expression of CXCR4, GSK3β and MMP-2. Cell invasion assay was used to detect the effect of the Akt pathway on CXCR4-induced GSK3β expression.
RESULTS: Overexpression of CXCR4 promoted GSK3β expression and silencing of CXCR4 suppressed GSK3β expression. Overexpression of CXCR4 activated cyclin D1 and p-Akt expression, but inhibited p21 expression. Silencing of CXCR4 had the reverse effect. CXCR4 promoted GSK3β expression and PANC-1 invasion by Akt signaling. CXCR4 upregulated GSK3β expression, at least in part, at the level of transcription.
CONCLUSIONS: CXCR4 promotes GSK3β expression via the Akt cell signaling pathway in pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25145299     DOI: 10.1007/s10147-014-0740-0

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  20 in total

1.  Beta-catenin is a promising key factor in the SDF-1/CXCR4 axis on metastasis of pancreatic cancer.

Authors:  Zheng Wang; Qingyong Ma
Journal:  Med Hypotheses       Date:  2007-03-26       Impact factor: 1.538

2.  Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the expression of β-catenin, leading to a rapid proliferation of pancreatic cells.

Authors:  Il-Rae Cho; Sang Seok Koh; Hye-Jin Min; Su Jin Kim; Yangsoon Lee; Eun-Hee Park; Srisuttee Ratakorn; Byung Hak Jhun; Sangtaek Oh; Randal N Johnston; Young-Hwa Chung
Journal:  Exp Mol Med       Date:  2011-02-28       Impact factor: 8.718

3.  GSK3 and PKB/Akt are associated with integrin-mediated regulation of PTHrP, IL-6 and IL-8 expression in FG pancreatic cancer cells.

Authors:  John J Grzesiak; Kathy C Smith; Douglas W Burton; Leonard J Deftos; Michael Bouvet
Journal:  Int J Cancer       Date:  2005-04-20       Impact factor: 7.396

4.  Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation.

Authors:  H D Park; Y Lee; Y K Oh; J G Jung; Y W Park; K Myung; K-H Kim; S S Koh; D-S Lim
Journal:  Oncogene       Date:  2010-08-30       Impact factor: 9.867

5.  SDF-1α upregulation of MMP-2 is mediated by p38 MAPK signaling in pancreatic cancer cell lines.

Authors:  Feng Pan; Shijie Ma; Weike Cao; Haining Liu; Fengli Chen; Xiaofei Chen; Ruihua Shi
Journal:  Mol Biol Rep       Date:  2013-05-28       Impact factor: 2.316

Review 6.  GSK3: a multifaceted kinase in Wnt signaling.

Authors:  Dianqing Wu; Weijun Pan
Journal:  Trends Biochem Sci       Date:  2009-10-31       Impact factor: 13.807

Review 7.  The peculiarities of the SDF-1/CXCL12 system: in some cells, CXCR4 and CXCR7 sing solos, in others, they sing duets.

Authors:  Malte Puchert; Jürgen Engele
Journal:  Cell Tissue Res       Date:  2013-11-29       Impact factor: 5.249

8.  Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo.

Authors:  Yan-Xi Sun; Jingcheng Wang; Charles E Shelburne; Dennis E Lopatin; Arul M Chinnaiyan; Mark A Rubin; Kenneth J Pienta; Russell S Taichman
Journal:  J Cell Biochem       Date:  2003-06-01       Impact factor: 4.429

Review 9.  Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.

Authors:  Peng-Fei Wu; Zi-Peng Lu; Bao-Bao Cai; Lei Tian; Chen Zou; Kui-Rong Jiang; Yi Miao
Journal:  Chin Med J (Engl)       Date:  2013       Impact factor: 2.628

10.  Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.

Authors:  Shadi Mamaghani; Satish Patel; David W Hedley
Journal:  BMC Cancer       Date:  2009-04-30       Impact factor: 4.430

View more
  5 in total

Review 1.  Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.

Authors:  Tasuku Matsuoka; Masakazu Yashiro
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

2.  Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells.

Authors:  Shu-Ting Pan; Yiru Qin; Zhi-Wei Zhou; Zhi-Xu He; Xueji Zhang; Tianxin Yang; Yin-Xue Yang; Dong Wang; Jia-Xuan Qiu; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-03-16       Impact factor: 4.162

Review 3.  Genetic factors affecting patient responses to pancreatic cancer treatment.

Authors:  George Fotopoulos; Konstantinos Syrigos; Muhammad Wasif Saif
Journal:  Ann Gastroenterol       Date:  2016-06-10

Review 4.  Glycogen Synthase Kinase 3β in Cancer Biology and Treatment.

Authors:  Takahiro Domoto; Masahiro Uehara; Dilireba Bolidong; Toshinari Minamoto
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

5.  The upregulation of stromal antigen 3 expression suppresses the phenotypic hallmarks of hepatocellular carcinoma through the Smad3-CDK4/CDK6-cyclin D1 and CXCR4/RhoA pathways.

Authors:  Menglin Zhao; Yanyan Wang; Yue Zhang; Xinwei Li; Jiaqi Mi; Qiang Wang; Zhijun Geng; Lugen Zuo; Xue Song; Sitang Ge; Zining Zhang; Mingyue Tang; Huiyuan Li; Zishu Wang; Chenchen Jiang; Fang Su
Journal:  BMC Gastroenterol       Date:  2022-08-08       Impact factor: 2.847

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.